Calcium Channel Inhibitory Effect of Marjoram (Origanum majorana L.): Its Medicinal Use in Diarrhea and Gut Hyperactivity

Najeeb Ur Rehman1,*, Mohd Nazam Ansari1, Wasim Ahmad2, Abuzer Ali3

1Department of Pharmacology & Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
2Department of Pharmacy, Mohammed Al-Mana College for Medical Sciences, Dammam 34222, Saudi Arabia
3Department of Pharmacognosy, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia

*Correspondence: n_rehman5@hotmail.com (Najeeb Ur Rehman)

1. Introduction

Most volatile oil-containing plants have been used as condiments to enhance the flavor of food since ancient times. Later on, a few species of volatile oil-containing plants were explored for managing diseases [1]. Plant families like Apiaceae, Asteraceae, Burseraceae, Lamiaceae, Lauraceae, Myrtaceae, and Zingiberaceae are known for their members containing volatile oils. In particular, members of the Lamiaceae (Labiatae) family have been explored to a massive extent during these days [2]. A few of the well-known members of the family Lamiaceae are marjoram, basil, mint, oregano, and thyme, which are used for culinary and medicinal purposes.

Marjoram (Origanum majorana L.) belongs to the family Lamiaceae, is widely recognized as sweet marjoram, and has been traditionally used for managing gastrointestinal and respiratory diseases [3,4]. Marjoram is indigenous to the Mediterranean region and the Arabian Peninsula. The ancient Greeks and Romans believed this plant was a symbol of happiness. It is a perennial bushy plant that reaches a height of up to 12 to 24 inches. The plant bears oval leaves, which are oppositely arranged with white or red flowers. Marjoram leaves are widely used for garnishing purposes. The leaves contain essential oil, and the oil obtained from the leaves is used in mouthwashes and rubbed topically in cases of nasal congestion [5]. Marjoram has been used extensively in pharmaceuticals and food due to its flavor and medicinal properties.

Due to the dynamic uses of this plant, several studies have reported its antioxidant effect [6,7], antibacterial effect [8], neurobiological activity [7], and skin protection effects [9]. Several studies related to its essential oil composition [10], Electrospray Ionisation Mass Spectrometry (ESI-MS) fingerprinting of essential oil [11], ratios of cis- and trans-Sabinene Hydroxy [12], determination of polyphenolic compounds [8,13,14], and the effects of blanching on the stability of polyphenols [15] have been reported. The development of nanoemulsions as well as pectin films [16] was also done for the essential oil of marjoram.

The constituents and concentration of the compounds in the plant vary due to factors like geographical variations, soil, and climatic conditions [17]. The essential
oil of marjoram majorly contributes to most of its activities. Similarly, the methanolic extract of marjoram possesses polyphenolic compounds, which majorly contribute to its antioxidant activity. Hence, for establishing a representative prototype of *O. majorana* L. from the Arabian Peninsula, it was worth carrying out a chemical analysis of the essential oil and the phenolic content of marjoram obtained from the Arabian Peninsula. The present study conducted a Gas chromatography–mass spectrometry (GC-MS)-assisted chemo profiling, an investigation of the antioxidants, and a detailed anti-diarrheal evaluation of the methanolic extract of *O. majorana* leaves.

2. Materials and Methods

2.1 Chemicals

The chemicals utilized in this study were obtained from Sigma Company, located in St. Louis, MO, USA, including carbachol (CCh), acetylcholine perchlorate (ACh), and verapamil. The physiological buffer solution (Tyrode’s) was prepared using salts acquired from Merck (Darmstadt, Germany). Castor oil was acquired from a local pharmacy in Al-Kharj. All chemicals used were of analytical quality.

2.2 Animals

Wistar albino rats (weighing 200–250 g) were used for the ex vivo study, while Swiss albino mice (weighing 30–35 g) were used for the in vivo study. These animals were obtained from the Animal Care Unit at the College of Pharmacy, Prince Sattam bin Abdulaziz University (PSAU), Saudi Arabia. They were kept under optimal conditions, with a temperature of 22 ± 1 °C, relative humidity of 55 ± 5%, and equal exposure to light and dark cycles. All animals were given a standardized pellet meal and unrestricted access to water. Prior to conducting the ex vivo studies, the rats underwent a 24-hour fasting period. Their cervical dislocation was performed after administering light anesthesia using diethyl ether, and the cessation of ear reflexes was used to certify their death. All tests, both in vivo and ex vivo, were conducted with meticulous attention to detail, adhering strictly to the directions outlined in National Research Council [18]. The study protocol has received approval from the Bio-Ethical Research Committee (BERC) at PSAU, with the reference number BERC-004-12-19.

2.3 Extraction of Plant Material

*O. majorana* leaves were purchased from the local market of Dammam and authenticated (PL/0445/2020-21/P-009) by the Department of Pharmacognosy, College of Clinical Pharmacy, Taif University, Saudi Arabia. The plant material was dried in the shade. All plant materials were crushed into a coarse size and later subjected to extraction.

2.4 Preparation of the Plant Extracts

The plant matter was crushed and macerated to prepare the extract. Ten grams of each sample were weighed into 500 mL Erlenmeyer flasks, and 100 mL of methanol was added to the plant samples. Extraction was carried out by the maceration technique with frequent agitation at room temperature for 5 days. After filtration through filter paper, the extracts of every sample were evaporated until the constant weight and respective extractives were calculated. The final residues were used in this study.

2.5 GC-MS Analysis

The phytochemical composition of the methanolic leaf extract of *O. majorana* was analyzed by Agilent GC-MS (7890A) using HP 5MS column (30 m × 0.25 mm × 0.25 µm film thickness) for the separation on split mode 1:20 with helium being used as the gaseous mobile phase at a flow rate of 1.0 mL per min. The injector temperature was 280 °C, the source temperature of MS was kept at 230 °C, and the Quad temperature was kept at 150 °C. The column oven temperature was increased from 150 °C to 300 °C at a gradual rise of 10 °C/min, and the total run time was 40 min. The scanning was carried out in the range of 40 to 600 mass while electron energy was kept at 70 eV. A solvent delay of 3 minutes was employed during the analysis. Identification of components was done by comparing the spectra of the sample with that of the standard spectra available with National Institute of Standards and Technology and Wiley library [19,20].

2.6 In Vivo Antidiarrheal Study

Altogether, twenty mice were assigned randomly to four groups, each containing an equal number of animals. After fasting for 18 hours, the mice in the first group were given a saline solution (10 mL/kg) through oral gavage and were labeled as the negative control group. Following the pilot screening to determine the appropriate dosage, the second and third groups (referred to as test groups) were administered orally with two escalating doses of 200 and 400 mg/kg of methanolic leaves extract of *O. majorana*, respectively. The fourth group of mice was administered loperamide at a dosage of 10 mg/kg and designated as the positive control group. Following one hour, all mice were administered castor oil orally at a dosage of 10 mL/kg. Each animal was then placed in an individual cage with a blotting sheet on the floor. This allowed a blind observer to determine the presence or absence of diarrhea. After four hours, the blotting sheet from each cage was examined for the presence of characteristic diarrheal droppings. The protective effect of the extract was evident when no instances of diarrhea were seen, as previously documented by Jebunnessa et al. [21].

[Image 478x52 to 541x66]
2.7 Ex Vivo Experiments on Isolated Rat Ileum

The study rats were euthanized, and the terminal portion of the small intestine (ileum) was extracted following the protocol described by Rehman et al. [22]. After being isolated, specific sections of ileal tissues measuring 2–3 cm in length were thoroughly cleaned to remove nearby tissues and fecal matter. These sections were then placed in emkaBath (France) and connected to a transducer and IOX software (version 2.9.10.6, emka technologies, SAS, Paris, France). The Tyrod solution (pH 7.4) was freshly prepared [22] and added to tissue baths with a volume of 20 mL. The baths were then filled with carbogen gas and maintained at a temperature of 37 °C. A stress of 0.7 grams was exerted by turning the transducer knob in a clockwise direction. The tissues were then allowed to stabilize for 30 minutes, during which they were exposed to acetylcholine numerous times at a concentration of 0.3 µM. Following stabilization, continuous muscle contractions were induced using CCh, and high doses of K⁺ and O. majorana were gradually introduced into the bathing solution, with concentrations increasing to a maximum final bath concentration (FBC) of 10 mg/mL.

2.8 Ca²⁺ Inhibitory Effect Confirmation

Following the first relaxation of O. majorana in response to high K⁺ levels, additional verification of Ca²⁺ channel blocking (CCB) was achieved by incubating the ileal tissues in a solution of Ca²⁺-free Tyrode’s solution combined with EDTA (0.1 mM) for 45 minutes. This solution was used to chelate Ca²⁺ ions. To further reduce the amount of Ca²⁺ inside the cells, the solution that did not contain Ca²⁺ was replaced with another solution called K⁺-rich and Ca²⁺-free Tyrode’s solution. The concentrations of the different components in this solution were as follows (in mM): potassium chloride: 50, sodium chloride: 91.03, sodium dihydrogen phosphate dehydrates: 0.32, sodium bicarbonate: 11.9, magnesium chloride hexahydrate: 0.50, glucose: 5.05. After incubating the solution for 45 minutes, CaCl₂-Concentration response curves (CRCs) were created with and without varying concentrations of O. majorana. The findings were then compared to the typical CCB drug, verapamil [23].

2.9 Statistics

The results have been reported as the mean ± standard error of the mean (SEM), and the number of experiments conducted has been denoted by “n”. The EC₅₀ values were determined, and their 95% confidence intervals (CI) were calculated. The statistical analysis involved two-way ANOVA, followed by Bonferroni’s post-test, to compare concentration-response curves (CRCs) with a control group. The effectiveness of diarrhea prevention was assessed using a statistical analysis, comparing all groups to a control group, using the Chi-square (χ²) test. A p-value less than 0.05 has been regarded as statistically significant.
Table 1. Phytoconstituents present in O. majorana leaves extract.

<table>
<thead>
<tr>
<th>S. No.</th>
<th>RT (min)</th>
<th>Area %</th>
<th>Compound name</th>
<th>Molecular weight</th>
<th>Molecular formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7.655</td>
<td>0.95</td>
<td>Sabinene</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>2</td>
<td>9.01</td>
<td>1.07</td>
<td>Alpha-thujene</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>3</td>
<td>10.30</td>
<td>2.96</td>
<td>Alpha-terpinene</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>4</td>
<td>10.65</td>
<td>2.77</td>
<td>Beta-Phellandrene</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>5</td>
<td>11.53</td>
<td>3.56</td>
<td>Gamma-terpinene</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>6</td>
<td>11.87</td>
<td>4.64</td>
<td>Beta-terpineol</td>
<td>154.25</td>
<td>C_{10}H_{18}O</td>
</tr>
<tr>
<td>7</td>
<td>12.66</td>
<td>4.19</td>
<td>Carane</td>
<td>138.25</td>
<td>C_{10}H_{18}</td>
</tr>
<tr>
<td>8</td>
<td>12.82</td>
<td>3.05</td>
<td>3-Formyl-1-methyl-2(1H)-pyridine-thione</td>
<td>153.20</td>
<td>C_{7}H_{7}NOS</td>
</tr>
<tr>
<td>9</td>
<td>13.34</td>
<td>3.04</td>
<td>1,3,6-Heptatriene, 2,5,5-trimethyl</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>10</td>
<td>15.07</td>
<td>3.05</td>
<td>Terpinen-4-ol</td>
<td>154.25</td>
<td>C_{10}H_{18}O</td>
</tr>
<tr>
<td>11</td>
<td>17.22</td>
<td>0.75</td>
<td>Linalyl acetate</td>
<td>196.29</td>
<td>C_{12}H_{20}O_{2}</td>
</tr>
<tr>
<td>12</td>
<td>19.42</td>
<td>0.17</td>
<td>1,3,6-Heptatriene, 2,5,5-trimethyl</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>13</td>
<td>21.59</td>
<td>3.06</td>
<td>Beta-caryophyllene</td>
<td>204.36</td>
<td>C_{15}H_{24}</td>
</tr>
<tr>
<td>14</td>
<td>23.53</td>
<td>1.30</td>
<td>Gamma-Pyronene</td>
<td>136.23</td>
<td>C_{10}H_{16}</td>
</tr>
<tr>
<td>15</td>
<td>29.61</td>
<td>1.24</td>
<td>Pinane</td>
<td>138.25</td>
<td>C_{10}H_{18}</td>
</tr>
<tr>
<td>16</td>
<td>30.66</td>
<td>5.68</td>
<td>Methyl palmitate</td>
<td>270.5</td>
<td>C_{17}H_{34}O_{2}</td>
</tr>
<tr>
<td>17</td>
<td>32.44</td>
<td>3.92</td>
<td>Methyl linoleate</td>
<td>294.5</td>
<td>C_{19}H_{34}O_{2}</td>
</tr>
<tr>
<td>18</td>
<td>32.52</td>
<td>13.30</td>
<td>Linoleic acid</td>
<td>280.4</td>
<td>C_{18}H_{32}O_{2}</td>
</tr>
<tr>
<td>19</td>
<td>32.64</td>
<td>1.53</td>
<td>Phytol</td>
<td>296.5</td>
<td>C_{20}H_{40}O</td>
</tr>
<tr>
<td>20</td>
<td>32.74</td>
<td>1.48</td>
<td>Methyl isostearate</td>
<td>298.5</td>
<td>C_{19}H_{38}O_{2}</td>
</tr>
<tr>
<td>21</td>
<td>35.05</td>
<td>1.42</td>
<td>Dehydroabeityl alcohol</td>
<td>290.5</td>
<td>C_{20}H_{34}O</td>
</tr>
</tbody>
</table>

S. No., Serial Number; RT, Retention Time.

Table 2. Antidiarrheal activity of the methanolic leaf extract of Origanum majorana (O. majorana) using mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose</th>
<th>No. of mice with diarrhea</th>
<th>% Protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castoroil</td>
<td>10 mL/kg</td>
<td>5/5</td>
<td>0</td>
</tr>
<tr>
<td>Castoroil + O. majorana</td>
<td>200 mg/kg</td>
<td>3*/5</td>
<td>40</td>
</tr>
<tr>
<td>Castoroil + O. majorana</td>
<td>400 mg/kg</td>
<td>1*/5</td>
<td>80</td>
</tr>
<tr>
<td>Castoroil + loperamide</td>
<td>10 mg/kg</td>
<td>0**/5</td>
<td>100</td>
</tr>
</tbody>
</table>

* p < 0.05 and ** p < 0.01 vs. Saline + Castoroil treated group (χ²-test).

3. Results

3.1 Methanolic Extract Yield (%)

The leaves of O. majorana yielded 14.7% of methanolic crude extract.

3.2 GC-MS Phytochemical Profiling

O. majorana was analyzed by GC-MS (Fig. 1). The phytoconstituents identified are listed in Table 1. GC-MS identified twenty-one constituents representing 96.27% of the extract. Alpha-terpineol (35.18%) and linoleic acid (13.3%) were characterized as major components of the methanolic extract. Sabinene, a bicyclic monoterpane found in the essential oils of various plant species, was also identified in the profiling.

3.3 Antidiarrheal Effect

Both the increasing doses of orally administered O. majorana extract in mice exhibited significant antidiarrheal effects in comparison to the control group (Table 2). When administered a dose of 200 mg/kg, two out of five mice exhibited protection, indicating a 40% protection rate. In contrast, a higher dose of 400 mg/kg resulted in 80% protection. The positive control drug, loperamide, showed 100% protection at 10 mg/kg, as detailed in Table 2.

3.4 Ex Vivo Antispasmodic Effects

When tested against CCh and high K⁺-mediated spasm in rat-isolated ileal tissues, O. majorana resulted in complete inhibition with a resultant EC₅₀ value of 1.38 mg/mL (1.06–1.82, 95% CI, n = 4) recorded against high K⁺ whereas the potency against CCh was found weak with a resultant EC₅₀ of 7.14 mg/mL (6.85–7.84, 95% CI, n = 4), as shown Fig. 2A. Similarly, verapamil resulted in distinctly higher potency to inhibit high K⁺ compared to CCh-evoked spasms.
Fig. 2. The concentration-response curves compare the inhibitory effect of the methanolic *Origanum majorana* (*O. majorana*) leaf extract (A) and verapamil (B) against carbachol (CCh, 1 µM) and high K⁺ (80 mM)-induced contractions in isolated rat ileum preparations. The values presented are the mean ± Standard error of the mean (SEM), n = 4.

spasms with EC₅₀ values of 0.24 µM (0.19–0.32, 95% CI, n = 4) and 2.28 µM (1.84–2.92, 95% CI, n = 4), respectively as shown in Fig. 2B.

3.5 Calcium Channel Blocking (CCB)-Like Effect

To further confirm the Ca⁺⁺ inhibitory effect, ileal tissues preincubated with *O. majorana* methanolic extract shifted the Ca⁺⁺ CRCs curves at tested concentrations of
0.3 and 1.0 mg/mL (Fig. 3A), similar to that caused by verapamil at concentrations of 0.03 and 0.10 µM (Fig. 3B).

4. Discussion

The therapeutic effect of *O. majorana* in digestive disorders [24,25] raised our interest in evaluating this plant scientifically using rodents and employing GC-MS to determine its phytochemical analysis. In the castor oil-induced diarrhea model, the preincubated mice with plant extract resulted in a dose-dependent antidiarrheal effect by protecting the mice from typical diarrheal drops at 200 and 400 mg/kg when compared to a saline pretreated group where no protection was observed. The dose selection of the plant extract was based on a previously reported acute toxicity study that revealed the safety of *O. majorana* ethanolic extract up to the maximum tested dose of 5 g/kg [26,27]. The induction of diarrhea in normal mice was achieved by administering castor oil, which, upon hydrolysis into ricinoleic acid, alters the transportation of electrolytes and water. This disruption leads to spasms in the gastrointestinal tract [28]. Thus, a potential antidiarrheal agent may exhibit its antidiarrheal effect by inhibiting bowel contraction. The antidiarrheal activity of the plant extract of *O. majorana* can be attributed to multiple inhibitory components present in the plant.

To identify the potential pharmacodynamics responsible for the observed antidiarrheal activity, the methanolic *O. majorana* extract was tested in increasing doses on isolated rat ileum, as previously documented [29]. Based on previous findings that antispasmodic medicines typically have inhibitory effects on the gut by blocking calcium channels [30], we conducted further experiments to assess the impact of *O. majorana* extract on induced contractions in rat ileum using CCh and high K⁺ as contractile agents [31]. The critical analysis of the pattern of the inhibitory CRCs of *O. majorana* against CCh and high K⁺ in the ileal tissues shows a verapamil-like effect by recording significantly higher potency (*p < 0.05*) against high K⁺ compared to CCh, which indicates the involvement of the predominant CCB-like components. Verapamil, a standard CCB, was run in parallel experiments [23,32] for comparison.

Godfraind *et al.* [33] reported that high concentrations of K⁺ (>30 mM) lead to depolarization of certain smooth muscles due to the activation of voltage-dependent Ca²⁺ channels (specifically, L-type channels), resulting in persistent contractions. A substance that reverses high K⁺ (>30 mM)-mediated spasm depicted CCBs [34,35]. Hence, to support and further confirm the CCB-like action of *O. majorana*, the ileal tissues were first made Ca²⁺-free by replacing the bath solution with Ca²⁺-free Tyrode’s solution having a chelating agent, ethylenediaminetetraacetic acid (EDTA) to chelate the Ca²⁺ from tissue. Calcium-free ileal tissues were then preincubated with increasing concentrations of *O. majorana*. The contractile CRCs of exogenously added Ca²⁺ were made in the absence and presence of preincubated tissues with *O. majorana*. *O. majorana* extract, at both preincubated concentrations, caused a rightward shift in Ca²⁺-CRCs and suppressed the highest peak, comparable to verapamil, a standard CCB [32]. This confirms the verapamil-like CCB impact of *O. majorana*. The GC-MS analysis of *O. majorana* extract showed the presence of twenty-one constituents, where alpha-terpineol was found to be the major compound in terms of concentration. Alpha-terpineol has been reported to possess antidiarrheal effects in mice [36]. Hence, the plant’s antidiarrheal and antispasmodic effect might be due to the presence of this compound, whereas the involvement of additional compounds may have a parallel contribution.

5. Conclusions

The study’s findings show that the methanolic leaf extract of *O. majorana* inhibits with higher potency the contractions against high K⁺ compared to CCh-mediated contractions and thus depicts that voltage-gated Ca²⁺ channels predominantly mediate the antidiarrheal and antispasmodic effects of the plant. However, additional mechanism(s) cannot be ignored.

 Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

 Author Contributions

NUR and WA designed the research study. MNA, NUR, AA, and WA performed the research. NUR, MNA, and WA analyzed the data. MNA, NUR, AA, and WA wrote the manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work. All authors read and approved the final manuscript.

 Ethics Approval and Consent to Participate

The study has obtained approval from the Bio-Ethical Research Committee (BERC) at PSAU, with the reference number BERC-004-12-19.

 Acknowledgment

The authors are thankful to the Department of Pharmacology and Toxicology, College of Pharmacy, PSAU, for providing the facility to perform the study.

 Funding

The authors extend their appreciation to Prince Sattam Bin Abdulaziz University for funding this research work through the project number (PSAU/2023/03/25570).

 Conflict of Interest

The authors declare no conflict of interest.
References


[31] Godfraid T, Miller R, Wibo M. Calcium antagonism and cal-

